- |||||||||| Campath (alemtuzumab) / Sanofi, Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System (clinicaltrials.gov) - Mar 5, 2019
P2, N=92, Completed,
Active, not recruiting --> Completed
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion date, Combination therapy: CAVALLI: A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL (clinicaltrials.gov) - Mar 5, 2019
P1/2, N=267, Active, not recruiting,
Active, not recruiting --> Completed Trial completion date: Feb 2020 --> Jun 2019
- |||||||||| sotigalimab (APX005M) / Apexigen
Trial initiation date, Combination therapy, Metastases: APX005M and Doxorubicin in Advanced Sarcoma (clinicaltrials.gov) - Mar 4, 2019
P2, N=27, Not yet recruiting,
Trial completion date: Feb 2019 --> Feb 2020 | Trial primary completion date: Feb 2019 --> Feb 2020 Initiation date: Dec 2018 --> Apr 2019
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: Magnesium Stabilized Multifunctional DNA Nanoparticles for Tumor-Targeted and pH-Responsive Drug Delivery. (Pubmed Central) - Mar 2, 2019
Here, a doxorubicin (Dox)-delivery nanoparticle for tumor-targeting chemotherapy is developed taking advantage of rolling circle amplification (RCA) technique, by which a high quantity of functional DNAs can be efficiently collected...Through cellular and in vivo experiments, we thoroughly demonstrate that this kind of Mg2+ stabilized multi-functional DNA nanoparticles can successfully realize tumor-targeted Dox delivery. Overall, exploiting RCA technique and Mg2+ condensation, this new strategy can fabricate nanoparticles with a non-toxic composition through a simple fabrication process and provides a good way to preserve and promote DNA functions, which will show a broad application potential in the biomedical field.
- |||||||||| Campath (alemtuzumab) / Sanofi
Trial completion, Enrollment change, Trial primary completion date, Combination therapy, IO biomarker: ACT-1: Alemtuzumab and CHOP in T-cell Lymphoma (clinicaltrials.gov) - Mar 1, 2019
P3, N=136, Completed,
Overall, exploiting RCA technique and Mg2+ condensation, this new strategy can fabricate nanoparticles with a non-toxic composition through a simple fabrication process and provides a good way to preserve and promote DNA functions, which will show a broad application potential in the biomedical field. Active, not recruiting --> Completed | N=308 --> 136 | Trial primary completion date: Apr 2015 --> Dec 2016
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment closed, Enrollment change, Trial primary completion date: IELSG30: Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis (clinicaltrials.gov) - Mar 1, 2019
P2, N=54, Active, not recruiting,
Active, not recruiting --> Completed | N=308 --> 136 | Trial primary completion date: Apr 2015 --> Dec 2016 Recruiting --> Active, not recruiting | N=35 --> 54 | Trial primary completion date: Jul 2017 --> Jun 2019
- |||||||||| Trial completion, Trial completion date, Combination therapy: ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Mar 1, 2019
P2, N=35, Completed,
Recruiting --> Active, not recruiting | N=35 --> 54 | Trial primary completion date: Jul 2017 --> Jun 2019 Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Aug 2018
- |||||||||| Trial completion date, Trial initiation date, Trial primary completion date, Metastases: Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma (clinicaltrials.gov) - Mar 1, 2019
P2, N=20, Recruiting,
Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Aug 2018 Trial completion date: Jul 2020 --> Jul 2021 | Initiation date: May 2016 --> Mar 2017 | Trial primary completion date: Jul 2019 --> Jul 2020
- |||||||||| Avastin (bevacizumab) / Roche, Herceptin (trastuzumab) / Roche
Trial completion: Neoadjuvant Treatment of Breast Cancer (clinicaltrials.gov) - Feb 28, 2019
P2, N=43, Completed,
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Review, Journal, IO biomarker: Should We Use Cell of Origin and Dual-protein Expression in Treating DLBCL? (Pubmed Central) - Feb 27, 2019
Treatment outcomes in diffuse large B-cell lymphoma (DLBCL) following standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy is highly variable and dependent on a number of clinical, biologic, and genetic features...Moving forward, clinical trials focusing on molecular subsets of DLBCL, and incorporating rational targeted agents, will ideally lead to improved outcomes and allow a more personalized treatment approach. This review will focus on emerging data regarding DLBCL management based on either COO or dual overexpression of MYC/BCL2 proteins.
- |||||||||| Lartruvo (olaratumab) / Eli Lilly
Trial completion, Trial completion date, Combination therapy, Monotherapy: A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma (clinicaltrials.gov) - Feb 22, 2019
P1b, N=51, Completed,
Trial completion date: Oct 2023 --> Jul 2022 Active, not recruiting --> Completed | Trial completion date: Jan 2020 --> Jul 2018
- |||||||||| cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial primary completion date: AKY15-HK-301_NEPA Study (clinicaltrials.gov) - Feb 22, 2019
P2, N=60, Recruiting,
Active, not recruiting --> Completed | Trial completion date: Jan 2020 --> Jul 2018 Trial primary completion date: Dec 2018 --> Dec 2019
- |||||||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients (clinicaltrials.gov) - Feb 21, 2019
P2, N=3, Terminated,
Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020 N=43 --> 3 | Trial completion date: Dec 2023 --> Sep 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2020 --> Sep 2018; Investigator decision to close study
- |||||||||| Trial completion date: TACAC: Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients (clinicaltrials.gov) - Feb 19, 2019
P2, N=167, Active, not recruiting,
N=43 --> 3 | Trial completion date: Dec 2023 --> Sep 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2020 --> Sep 2018; Investigator decision to close study Trial completion date: Sep 2017 --> Sep 2020
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal: Development of Hepatic Steatosis After Chemotherapy for Non-Hodgkin Lymphoma. (Pubmed Central) - Feb 16, 2019
In this retrospective case-control study, adult patients with NHL were treated with rituximab, cyclophosphamide, doxorubicin, prednisone, and vincristine (R-CHOP) or R-CHOP + etoposide (EPOCH-R)...Etoposide-containing regimens were associated with a shorter time to steatosis (median 34 weeks versus 154 weeks; P < 0.001) despite similar baseline risk factors. The recovery period from NHL chemotherapy appears to be a "hot spot" for development of fatty liver, driven by early posttreatment weight gain, especially in subjects with baseline risk factors.
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion date, Trial primary completion date: Trial of DA-EPOCH Regimen for NHL With HLH (clinicaltrials.gov) - Feb 16, 2019
P2, N=50, Active, not recruiting,
Active, not recruiting --> Suspended Trial completion date: Apr 2014 --> Apr 2019 | Trial primary completion date: Oct 2013 --> Oct 2018
- |||||||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche, Tecentriq (atezolizumab) / Roche
Enrollment open, PD(L)-1 Biomarker, Metastases: APTneo: Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer (clinicaltrials.gov) - Feb 15, 2019
P3, N=650, Recruiting,
Trial completion date: Mar 2025 --> Jun 2025 | Initiation date: Mar 2019 --> Jun 2019 | Trial primary completion date: Mar 2024 --> Jun 2024 Not yet recruiting --> Recruiting
- |||||||||| Neupogen (filgrastim) / Kyowa Kirin, Amgen, Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche, Matulane (procarbazine hydrochloride) / Leadiant Biosci
Trial completion date, Trial primary completion date, FDG PET, Metastases: CRUK-07/146: Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma (clinicaltrials.gov) - Feb 12, 2019
P3, N=1202, Active, not recruiting,
The use of FAS before liver resection is associated with improved OS compared with surgery alone among patients with advanced synchronous pancreatic neuroendocrine liver metastases. Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Dec 2018 --> Jun 2019
- |||||||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open: Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer (clinicaltrials.gov) - Feb 12, 2019
P2, N=75, Recruiting,
Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Dec 2018 --> Jun 2019 Not yet recruiting --> Recruiting
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal: Targeting nucleolin for better survival in diffuse large B-cell lymphoma. (Pubmed Central) - Feb 11, 2019
These findings are of clinical importance because low nucleolin levels versus high nucleolin levels in DLBCL predicted 90 month estimated survival of 70 versus 12% (P<0.0001) of patients treated with R-CHOP based therapy.Leukemia accepted article preview online, 10 July 2017. doi:10.1038/leu.2017.215.
- |||||||||| Adcetris (brentuximab vedotin) / Seagen, Takeda
Clinical, P3 data, Clinical Trial,Phase I, Clinical Trial,Phase II, Clinical Trial,Phase III, Journal: Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. (Pubmed Central) - Feb 10, 2019
P3
doi:10.1038/leu.2017.215. Front-line treatment with A+CHP is superior to CHOP for patients with CD30-positive peripheral T-cell lymphomas as shown by a significant improvement in progression-free survival and overall survival with a manageable safety profile.
- |||||||||| Torisel (temsirolimus) / Pfizer
Trial completion date, Trial primary completion date: Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer (clinicaltrials.gov) - Feb 8, 2019
P3, N=253, Active, not recruiting,
Front-line treatment with A+CHP is superior to CHOP for patients with CD30-positive peripheral T-cell lymphomas as shown by a significant improvement in progression-free survival and overall survival with a manageable safety profile. Trial completion date: Dec 2018 --> Jul 2020 | Trial primary completion date: Dec 2018 --> Jul 2020
- |||||||||| Lartruvo (olaratumab) / Eli Lilly
Trial completion date, Combination therapy, Monotherapy: A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma (clinicaltrials.gov) - Feb 6, 2019
P1b, N=61, Active, not recruiting,
These results validate this modular synthesis route as an ideal platform for the development of sophisticated nanocarriers for future drug delivery applications. Trial completion date: Jun 2019 --> Jan 2020
- |||||||||| Herceptin (trastuzumab) / Roche
Enrollment closed, Surgery: Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery (clinicaltrials.gov) - Feb 5, 2019
P2, N=122, Active, not recruiting,
Low sucrose, EPA + DHA diets may attenuate neuroinflammation and synaptic damage induced by doxorubicin-based chemotherapy in specific brain regions. Completed --> Active, not recruiting
- |||||||||| Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion, Enrollment change, Trial completion date, Combination therapy: Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Feb 5, 2019
P1/2, N=35, Completed,
Completed --> Active, not recruiting Active, not recruiting --> Completed | N=56 --> 35 | Trial completion date: Nov 2017 --> Aug 2017
|
